On this page

Neomycin and Polymyxin B Sulfates and Hydrocortisone

Neomycin Sulfate, Polymyxin B Sulfate, Hydrocortisone · Solution/ Drops

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Neomycin and Polymyxin B Sulfates and Hydrocortisone
Generic name
Neomycin Sulfate, Polymyxin B Sulfate, Hydrocortisone
Dosage form
Solution/ Drops
Route
Auricular (Otic)
Marketing category
ANDA · ANDA
Labeler
Proficient Rx LP
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
8
Packages
8
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone 10 mg/mL 604449 View
Neomycin Sulfate 3.5 mg/mL 204602 View
Polymyxin B Sulfate 10000 [USP'U]/mL 204602 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution/ Drops
Route of administration
Auricular (Otic)
Presentations
16

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members
Polymyxin-class Antibacterial [EPC] EPC All 55 members
Polymyxins [CS] CS All 55 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
064053
Application type
ANDA · Abbreviated New Drug Application
Approval date
December 29, 1995
Sponsor
BAUSCH AND LOMB INC
Products on application
1
Submissions recorded
26
Products approved under application 064053.
Product Trade name Form Strength Ingredient Status TE Flags
064053-001 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE SOLUTION/DROPS HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Prescription AT RS

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 064053.
Type No. Action Status Date Review
Supplement 33 Labeling Approved July 3, 2006 —
Supplement 24 Manufacturing (CMC) Approved April 17, 2002 —
Supplement 22 Manufacturing (CMC) Approved March 28, 2002 —
Supplement 23 Labeling Approved March 15, 2002 —
Supplement 21 Manufacturing (CMC) Approved March 15, 2002 —
Supplement 19 Manufacturing (CMC) Approved March 15, 2002 —
Supplement 20 Manufacturing (CMC) Approved November 27, 2001 —
Supplement 18 Manufacturing (CMC) Approved July 30, 2001 —
Supplement 17 Manufacturing (CMC) Approved March 7, 2001 —
Supplement 16 Manufacturing (CMC) Approved February 2, 2001 —
Supplement 15 Manufacturing (CMC) Approved January 31, 2001 —
Supplement 14 Manufacturing (CMC) Approved June 27, 2000 —
Supplement 12 Manufacturing (CMC) Approved May 18, 2000 —
Supplement 10 Manufacturing (CMC) Approved April 28, 2000 —
Supplement 13 Manufacturing (CMC) Approved March 28, 2000 —
Supplement 11 Manufacturing (CMC) Approved June 7, 1999 —
Supplement 4 Manufacturing (CMC) Approved December 29, 1998 —
Supplement 8 Manufacturing (CMC) Approved November 19, 1998 —
Supplement 5 Manufacturing (CMC) Approved October 22, 1998 —
Supplement 9 Manufacturing (CMC) Approved September 18, 1998 —
Supplement 7 Manufacturing (CMC) Approved May 7, 1998 —
Supplement 6 Manufacturing (CMC) Approved May 7, 1998 —
Supplement 3 Manufacturing (CMC) Approved September 3, 1997 —
Supplement 2 Manufacturing (CMC) Approved April 29, 1997 —
Supplement 1 Manufacturing (CMC) Approved June 6, 1996 —
Original application 1 Approved December 29, 1995 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251107). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251107 HUMAN PRESCRIPTION DRUG · 20240606 HUMAN PRESCRIPTION DRUG · 20210101 HUMAN PRESCRIPTION DRUG · 20201030

Boxed Warning

openFDA Drug Labeling

FOR USE IN THE EARS ONLY NOT FOR USE IN THE EYES

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, four drops of the solution should be instilled into the affected ear 3 or 4 times daily. For infants and children, three drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the solution. This wick should be kept moist by adding further solution every 4 hours. The wick should be replaced at least once every 24 hours.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: This product is contraindicated in those individuals who have shown hypersensitivity to any of its components. This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (for example, herpes simplex virus or varicella zoster virus).

WARNINGS: Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk of ototoxicity is greater with prolonged use; therefore, duration of therapy should be limited to 10 consecutive days (see PRECAUTIONS - General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Due to its acidity, which may cause burning and stinging, Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution should not be used in any patients with a perforated tympanic membrane., Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. Discontinue this product promptly if sensitization or irritation occurs. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling and itching; it may be manifested simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter. Contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS ). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population 2 . In another study, the incidence was found to be approximately 1% 3 . Skin hyperpigmentation has been reported with polymyxin B containing products. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution, USP is a sterile antibacterial and anti-inflammatory solution for otic use. Each mL contains: ACTIVES : Neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%); INACTIVES : Propylene Glycol, Hydrochloric Acid, Potassium Metabisulfite, Cupric Sulfate, Glycerin, Purified Water. The pH range is 2.0 to 4.5. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 micrograms of neomycin standard per milligram, calculated on an anhydrous basis. The structural formulae are: Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa , (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per milligram, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β, 17, 21 - trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: C 21 H 30 O 5 Mol. Wt. 362.46 Neomycin Sulfate (structural formula) Polymyxin B Sulfate (structural formula) Hydrocortisone (structural formula)

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Neomycin and Polymyxin B Sulfates and Hydrocortisone Otic Solution, USP is supplied as clear, colorless solution filled in 10 mL low density polyethylene white opaque bottle, low density polyethylene white opaque nozzle and high density polyethylene white opaque cap. They are available as follow: 10 mL Bottle: NDC 60219-2083-1 Store at 15° to 25°C (59° to 77°F). This product’s labeling may have been updated. For the most recent prescribing information, please visit www.amneal.com.

Adverse event reports

Source: openFDA FAERS
123,956
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-0433-0 50090-0433 A-S Medication Solutions 1 BOTTLE, DROPPER in 1 CARTON (50090-0433-0) / 10 mL in 1 BOTTLE, DROPPER June 29, 2016
60219-2083-1 60219-2083 Amneal Pharmaceuticals NY LLC 1 BOTTLE in 1 CARTON (60219-2083-1) / 10 mL in 1 BOTTLE October 29, 2025
76420-104-10 76420-104 Asclemed USA, Inc. 10 mL in 1 BOTTLE, DROPPER (76420-104-10) October 30, 2020
24208-631-10 24208-631 Bausch & Lomb Incoporated 1 BOTTLE, DROPPER in 1 CARTON (24208-631-10) / 10 mL in 1 BOTTLE, DROPPER December 29, 1995
68071-4174-1 68071-4174 NuCare Pharmaceuticals,Inc. 10 mL in 1 BOX (68071-4174-1) December 5, 2017
63187-270-10 63187-270 Proficient Rx LP 1 BOTTLE, DROPPER in 1 CARTON (63187-270-10) / 10 mL in 1 BOTTLE, DROPPER February 2, 2015
70518-0763-0 70518-0763 REMEDYREPACK INC. 1 BOTTLE, DROPPER in 1 CARTON (70518-0763-0) / 10 mL in 1 BOTTLE, DROPPER October 6, 2017
85766-249-10 85766-249 Sportpharm LLC 1 BOTTLE, DROPPER in 1 CARTON (85766-249-10) / 10 mL in 1 BOTTLE, DROPPER July 17, 2026
50090-0433 50090-0433 A-S Medication Solutions — December 29, 1995
60219-2083 60219-2083 Amneal Pharmaceuticals NY LLC — October 29, 2025
76420-104 76420-104 Asclemed USA, Inc. — December 29, 1995
24208-631 24208-631 Bausch & Lomb Incoporated — December 29, 1995
68071-4174 68071-4174 NuCare Pharmaceuticals,Inc. — December 29, 1995
63187-270 63187-270 Proficient Rx LP — December 29, 1995
70518-0763 70518-0763 REMEDYREPACK INC. — October 6, 2017
85766-249 85766-249 Sportpharm LLC — December 29, 1995

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.